Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBC

This study tests stereotactic radiotherapy (highly precise, high-dose radiation) combined with adebrelimab (an immune checkpoint inhibitor) and chemotherapy (carboplatin and paclitaxel) for people with locally advanced non-small cell lung cancer (NSCLC). The goal is to shrink the tumor and improve outcomes. **You may be eligible if...** - You are 18 or older with locally advanced non-small cell lung cancer (Stage III) - Your disease has not spread to distant organs - Your general health and lung function allow chemotherapy and radiation - You have not had prior systemic cancer treatment for this cancer **You may NOT be eligible if...** - Your cancer has spread beyond the chest (Stage IV) - You have active autoimmune disease - You have severe lung disease (COPD, pulmonary fibrosis) that makes treatment risky - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.